Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC-402
- Development stage
- Phase 1
- Lead developer
- ViroCure
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral
01
Overview
RC-402 (ReoCure) is an oncolytic virus therapy developed by ViroCure Australia, a subsidiary of ViroCure Inc. It utilizes a naturally occurring, non-pathogenic mammalian orthoreovirus (reovirus) that selectively replicates in and lyses cancer cells, particularly those with activated Ras signaling pathways. Beyond direct viral oncolysis, RC-402 induces immunogenic cell death, which releases tumor-associated antigens and promotes a pro-inflammatory microenvironment to stimulate a systemic anti-tumor immune response. It is currently in Phase 1 clinical development for the treatment of advanced malignant solid tumors, including colorectal cancer and colorectal liver metastases. RC-402 is being evaluated both as a monotherapy and in combination with the PD-1 inhibitor pembrolizumab (Keytruda) to potentially enhance therapeutic efficacy through synergistic immune activation.
- Brand names
- ReoCure
- Other names
- ReoCure
Beyond the preview
Go deeper on RC-402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC-402.